Clinical Trial Update: Low-Dose Sirolimus to Increase Hematopoietic Function in Patients With RUNX1 Familial Platelet Disorder [Phase 2]

View source ↗

Summary

A Phase 2 clinical trial update describes evaluating low-dose sirolimus to improve hematopoietic function in patients with familial platelet disorder caused by …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Familial Platelet Disorder with Runx1 Mutation

Drugs mentioned

• Sirolimus (Sirolimus)

Snippet

Sponsor: M.D. Anderson Cancer Center | Conditions: Familial Platelet Disorder, Hematopoietic | Phase 2 | Status: RECRUITING